TQ Therapeutics GmbHCell therapiesFaster to the bedside: Collaboration in cell therapy of Fresenius Kabi and TQ TherapeuticsFresenius Kabi and TQ Therapeutics have entered into a strategic development agreement in cell and gene therapy. Fresenius Kabi receives an exclusive licence to develop, manufacture and distribute products … more ➔
BioNTech SEBioNTech2026: A year of reckoning for BioNTechFor BioNTech, 2026 could become one of the most decisive years since its pandemic-driven breakthrough. The pipeline is broad, the coffers are well stocked, partnerships are numerous, and the outlook … more ➔
M&AEli Lilly-Abivax €15 billion takeover rumor stirs markets, but no formal steps confirmedWhile much of the biotech industry is focused on meetings and dealmaking at the J.P. Morgan (JPM) Healthcare Conference, a rumor has cut through the JPM noise. The possibility of Eli Lilly making a move … more ➔
Fundingbit.bio closes a $50 million series C round after its 2025 restructuringbit.bio has raised $50 million in a series C round led by M&G Investments to support the next phase of its human cell programming business. The Cambridge-based company develops defined human cells using … more ➔
RocheRocheSecond time around: Roche’s return to MediLink underlines the value of the first dealRoche is back in China — and this time at a very different price point. In a renewed partnership with MediLink Therapeutics, the Swiss pharmaceutical group has secured a second antibody–drug conjugate … more ➔
Freepik.comJohnson & JohnsonNumab’s billion-dollar antibody deal takes an unexpected turnJust over a year and a half ago, Swiss biotech Numab AG, based in Horgen on Lake Zurich, made the headlines when it sold a single antibody to Johnson & Johnson for US$1.25 billion via a spin-out vehicle. … more ➔
Bayer AGCovid-19Better late than never: Bayer eyes a slice of the mRNA vaccine piePatent disputes are part of everyday life in pharma. What is unusual is the timing. More than three years after the peak of the Covid-19 pandemic, Bayer has launched a broad patent offensive against … more ➔
Seed financingEnodia Therapeutics raises €20.7m seed round for targeted protein degradation pipelineParis-based start-up Enodia Therapeutics has secured €20.7 million in seed funding to advance its early-stage pipeline of targeted protein degradation. Elaia, Pfizer Ventures and Bpifrance led the … more ➔
Picture from Ferdinand Stöhr on Unsplash Series A financing French investor Andera makes a $227m bet on U.S. obesity and asthma innovationParis-based private equity firm Andera Partners has kicked off 2026 with a surge of cross-border activity, leading two significant Series A financings for U.S. life sciences ventures. The back-to-back … more ➔
Photo from Giulia Bertelli on Unsplash Seed financingTECregen raises €11m seed round to advance thymus regenerationSwiss biotechnology company TECregen, based in Basel, has raised CHF 10 million (about €11 million) in seed financing to advance therapies designed to restore immune function by regenerating the thymus, … more ➔
TQ Therapeutics GmbH
BioNTech SE
Roche
Freepik.com
Bayer AG
Picture from Ferdinand Stöhr on Unsplash 
Photo from Giulia Bertelli on Unsplash